MIT Tech Review: AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.

AI automation throughout the drug development pipeline is opening up the possibility of faster, cheaper pharmaceuticals. Apriori’s CEO Lovisa Afzelius spoke with MIT Tech Review about how the Octavia platform uses artificial intelligence to develop vaccines capable of protecting people from a wide range of viral variants. 

Read more.